Literature DB >> 7002067

Reduced prostacyclin activity in systemic lupus erythematosus.

B A McVerry, S J Machin, H Parry, A H Goldstone.   

Abstract

When fresh rabbit aorta is incubated with plasma, prostacyclin, a potent inhibitor of platelet aggregation, is normally released. Plasma obtained from 2 patients with systemic lupus erythematosus (SLE) inhibited prostacyclin activity, while plasma from 22 other patients with SLE and 40 normal control subjects showed normal activity. Absence of prostacyclin activity did not appear to correlate with the clinical severity of the underlying disease. The possible association of this finding and the presence of thrombotic lesions in both patients is discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7002067      PMCID: PMC1000597          DOI: 10.1136/ard.39.5.524

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  5 in total

1.  Thrombosis of renal veins and inferior vena cava complicating lupus nephritis.

Authors:  C R Hamilton; P A Tumulty
Journal:  JAMA       Date:  1968-12-02       Impact factor: 56.272

2.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.

Authors:  S Moncada; R Gryglewski; S Bunting; J R Vane
Journal:  Nature       Date:  1976-10-21       Impact factor: 49.962

3.  Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on subendothelium.

Authors:  H J Weiss; V T Turitto
Journal:  Blood       Date:  1979-02       Impact factor: 22.113

4.  Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity?

Authors:  G Remuzzi; R Misiani; D Marchesi; M Livio; G Mecca; G de Gaetano; M B Donati
Journal:  Lancet       Date:  1978-10-21       Impact factor: 79.321

5.  Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.

Authors:  S Moncada; E A Higgs; J R Vane
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

  5 in total
  8 in total

1.  The lupus anticoagulant, pulmonary thromboembolism, and fatal pulmonary hypertension.

Authors:  B M Rothschild
Journal:  Ann Rheum Dis       Date:  1985-05       Impact factor: 19.103

2.  Pulmonary hypertension in systemic lupus erythematosus.

Authors:  A Oktay; A Oto
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-26

3.  Pulmonary hypertension in MCTD: report of two cases with anticardiolipin antibody.

Authors:  M Miyata; S Kida; T Kanno; K Suzuki; H Watanabe; S Kaise; T Nishimaki; Y Hosoda; R Kasukawa
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

Review 4.  The 'antiphospholipid syndrome' and the 'lupus anticoagulant'.

Authors:  J S Cameron; G Frampton
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

5.  The lupus anticoagulant, pulmonary thromboembolism, and fatal pulmonary hypertension.

Authors:  N E Anderson; M R Ali
Journal:  Ann Rheum Dis       Date:  1984-10       Impact factor: 19.103

6.  Stroke as an early manifestation of systemic lupus erythematosus.

Authors:  L F Haas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-06       Impact factor: 10.154

7.  Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant.

Authors:  M L Boey; C B Colaco; A E Gharavi; K B Elkon; S Loizou; G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-08

8.  Gangrene developing after minor surgery in a patient with undiagnosed systemic lupus erythematosus and lupus anticoagulant.

Authors:  B K Jindal; M F Martin; A Gayner
Journal:  Ann Rheum Dis       Date:  1983-06       Impact factor: 19.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.